Pharma Novartis raises forecast again after strong start to the year
Novartis has continued the strong pace of growth of recent quarters in the first three months of 2025. Contrary to the expectations of many analysts, the pharmaceutical company has raised its outlook again - for the ninth quarter in a row.
29.04.2025, 07:13
SDA
Between January and March, Novartis generated sales of USD 13.2 billion. This is an increase of 12 percent compared to the same period last year, as the Group announced on Tuesday. At constant exchange rates (CER), growth amounted to 15 percent.
In operational terms, the Basel-based company earned just under 4.7 billion US dollars (+38 percent) in the first quarter. The bottom line was a consolidated profit of 3.6 billion after 2.7 billion in the same period of the previous year. The increase was mainly due to the higher operating result, according to the press release.
For analysts, however, the core operating profit adjusted for various factors is more important. At 5.6 billion, this was better than the AWP consensus in the first quarter.
Novartis management is once again raising its own target for the full year. At constant exchange rates, the Group is now aiming for sales growth in the high single-digit percentage range (previously: mid to high single-digit range). For core operating profit, it is now forecasting growth in the low double-digit percentage range (previously: high single-digit to low double-digit range).
